http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Prabin Gyawali ),( Jyoti S Takanche ),( Bijay Krishna Prajapati ),( Rajendra Koju ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Thyroid dysfunction (TD) and metabolic syndrome (Met S) are known risk factors for atherosclerotic cardiovascular disease (ASCVD). TD is risk factor for ASCVD mediated by the effects of thyroid hormones on lipid metabolism and blood pressure hence the components of Met S. Although traditional lipid profile parameters are used to manage ASCVD in patients with Met S, there are no reliable biochemical parameters that can be used in early prediction, diagnosis and primary prevention. Nevertheless, recent studies have recognized serum lipid ratios, atherogenic index of plasma (AIP) and non- HDL Cholesterol (non-HDL-C) as a stronger predictive marker of coronary atherosclerosis and ASCVD events than isolated parameters used independently. Thus, the purpose of this study was to evaluate -the pattern of TD in patients with Met S and - serum lipid ratios, non-HDL cholesterol, and AIP as a predictor of ASCVD in patients with Met S. Methods: Between, October 2012 and March 2014, total of 358 previously diagnosed patients with Met S and 341 healthy controls, who visited diabetes and endocrine clinic at Dhulikhel Hospital, Dhulikhel, Nepal were recruited in the study. The thyroid function test parameters were measured to classify TD and the serum lipid concentrations were measured to calculate the lipid ratios, non-HDL-C and AIP. Results: The overall prevalence of TD in patients with Met S was 31.84 % with high prevalence of subclinical hypothyroidism. Patients with Met S had significantly higher significantly higher lipid ratio`s, non-HDL-C (165.78±48.66 vs 135.21±47.88), and AIP levels (0.810±0.023 vs 0.546±0.014) compared to healthy controls (P < 0.05). Conclusions: Patients with Met S develop sub-clinical hypothyroidism greatly. The measurements of serum lipid ratios, non HDL-C, and AIP level predicts high risk of developing ASCVD in patients with Met S.